Effect of Percutaneous Kyphoplasty Combined with Denosumab on Patients with Osteoporotic Vertebral Compression Fractures
Objective:To investigate the effect of percutaneous kyphoplasty combined with Denosumab on patients with osteoporotic vertebral compression fracture. Method:A total of 80 patients with osteoporotic vertebral compression fracture treated in Wuxi No.8 People's Hospital from July 2019 to July 2023 were selected and divided into two groups by random drawing method. The control group (40 cases) received percutaneous kyphoplasty,while the observation group (40 cases) was additionally treated with Denosumab on the basis of control group. The level of bone metabolism,bone mineral density,lumbar function,pain degree before and after treatment,and occurrence of adverse reactions were compared between the two groups. Result:After 6 months of treatment,the levels of procollagen type Ⅰ N-prepeptide (P1NP),C-terminal telopeptide of type Ⅰ collagen β degradation products (β-CTx),modified Oswestry disability index (ODI) and visual analogue scale (VAS) scores in the observation group were lower than those in the control group,and the bone density of lumbar spine and hip were higher than those in the control group,the differences were statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion:In the treatment of osteoporotic vertebral compression fractures,the combination of percutaneous kyphoplasty and Denosumab can effectively reduce the level of bone metabolic markers,increase bone mineral density of lumbar spine and hip,improve lumbar function and alleviate pain,with good safety.
DenosumabOsteoporotic vertebral compression fracturePercutaneous kyphoplastyBone metabolismBone density
万方数据
维普
